1A Stock Chart & Stats
€123.30
€1.85(1.52%)
At close: 4:00 PM EDT
€123.30
€1.85(1.52%)
Day’s Range― - ―
52-Week Range€55.00 - €188.00
Previous CloseN/A
Volume0.00
Average Volume (3M)9.00
Market Cap
€37.60B
Enterprise Value€41.35K
Total Cash (Recent Filing)€1.76B
Total Debt (Recent Filing)€3.95B
Price to Earnings (P/E)31.0
Beta0.66
Next Earnings
Nov 30, 2026EPS Estimate
1.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.09
Shares Outstanding282,431,950
10 Day Avg. Volume17
30 Day Avg. Volume9
Financial Highlights & Ratios
PEG Ratio9.44
Price to Book (P/B)6.14
Price to Sales (P/S)5.96
P/FCF Ratio35.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€147.37Price Target Upside19.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)5.2
Revenue Forecast (FY)€6.39B
Bulls Say, Bears Say
Bulls Say
Recurring Revenue And Switching CostsAgilent’s instrument base creates recurring demand for consumables, services and software. Validated methods, compliance requirements and integrated workflows raise switching costs, supporting customer retention and more resilient revenue over the medium term.
Raised Growth And Margin OutlookHigher full-year revenue and EPS guidance, alongside planned margin expansion, indicates improving execution and demand across several end markets. If sustained, this should support earnings growth beyond a single quarter and strengthen operating leverage.
Strong Free Cash FlowRobust free cash flow gives Agilent flexibility to fund research, capacity, acquisitions and shareholder returns while managing debt. High conversion from earnings also supports the durability of its profitable laboratory-solutions model.
Bears Say
Gross-Margin CompressionThe sharp decline in gross margin suggests mix, pricing or cost pressures that could be structural rather than temporary. Persistent compression would reduce operating leverage and limit the earnings benefit of continued revenue growth.
Higher Debt And Reduced FlexibilityAlthough leverage remains moderate, rising debt increases fixed financial obligations and reduces flexibility if laboratory capital spending weakens. Higher borrowing may also constrain investment or shareholder returns during a prolonged slowdown.
Operating Cash Flow Conversion DragOperating cash flow has not consistently matched accounting earnings, indicating working-capital or timing drag. Continued weak conversion could make cash generation more volatile and reduce the reliability of funding for investment, debt service and capital returns.
Agilent News
1A FAQ
What was Agilent’s price range in the past 12 months?
Agilent lowest stock price was €55.00 and its highest was €188.00 in the past 12 months.
What is Agilent’s market cap?
Agilent’s market cap is €37.60B.
When is Agilent’s upcoming earnings report date?
Agilent’s upcoming earnings report date is Nov 30, 2026 which is in 94 days.
How were Agilent’s earnings last quarter?
Agilent released its earnings results on Aug 26, 2026. The company reported €1.391 earnings per share for the quarter, beating the consensus estimate of €1.277 by €0.113.
Is Agilent overvalued?
According to Wall Street analysts Agilent’s price is currently Undervalued.
Does Agilent pay dividends?
Agilent does not currently pay dividends.
What is Agilent’s EPS estimate?
Agilent’s EPS estimate is 1.48.
How many shares outstanding does Agilent have?
Agilent has 282,431,950 shares outstanding.
What happened to Agilent’s price movement after its last earnings report?
Agilent reported an EPS of €1.391 in its last earnings report, beating expectations of €1.277. Following the earnings report the stock price went up 3.276%.
Which hedge fund is a major shareholder of Agilent?
Currently, no hedge funds are holding shares in IT:1A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agilent Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€147.37 (19.52% Upside)
€147.37 (19.52% Upside)
Blogger Sentiment
Bullish
IT:1A Sentiment 80%
Sector Average 60%
Sector Average 60%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.06%
12-Months-Change
Fundamentals
Return on Equity
0.52%
Trailing 12-Months
Asset Growth
7.46%
Trailing 12-Months
Company Description
Agilent
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
1A Company Deck
1A Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: solid top-line beats, meaningful margin expansion (noting some benefit from one-time tariff refunds), raised full-year guidance, robust cash generation, continued product and China momentum, and visible benefits from the Ignite transformation. Lowlights were largely timing, one-time refund effects, regional softness in pockets (Europe, parts of C&E) and near-term variability related to CDMO ramp timing and macro/cost pressures. On balance the positives substantially outweighed the negatives.View all IT:1A earnings summaries1A Revenue Breakdown
39.23% Life Sciences and Diagnostics Markets
41.85% Agilent CrossLab
18.91% Applied Markets

1A Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€147.37
▲(19.52% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month












